6q25.1-q25.3 Microdeletion in a Chinese Girl

© Mian-Ling Zhong1, © Ye-Mei Song1,2, © Chao-Chun Zou1

1Children’s Hospital of Zhejiang University Faculty of Medicine, Department of Endocrinology; National Clinical Research Center for Child Health, Huzhou, China
2Huzhou Center Hospital, Clinic of Pediatrics, Huzhou, China

What is already known on this topic?

6q25 microdeletion, a rare chromosome disorder, has been associated with growth restrictions, abnormal head shape, craniofacial anomalies, hypotonia, seizures, and mild to moderate intellectual disability.

What this study adds?

We reported a Chinese patient with an 8.1-Mb deletion involving 6q25.1-q25.3. Our patient shared the phenotypic features of the 6q25 microdeletion, including dysmorphic features with dysgenesis of the corpus callosum, growth retardation, intellectual disability, and language delay. In patients with dysmorphic features, microcephaly, growth retardation, intellectual disability, language delay and corpus callosum dysgenesis, 6q25 microdeletion should be considered in the differential diagnosis and chromosomal microarray analysis should be performed to confirm the diagnosis.

Abstract

Deletions of the long arm of chromosome 6 are rare and are characterized by great clinical variability according to the deletion breakpoint. Herein, we reported a 3-year-old girl evaluated for facial dysmorphism (long and connected eyebrows, big mouth, wide nasal bridge, high palate arch, low set ears, and thin hair), growth retardation, intellectual disability, and language delay. Chromosomal microarray analysis revealed an 8.1-Mb deletion within 6q25.1-q25.3 ([hg19] chr6: 152,307,705-160,422,834) comprising 31 genes. Dysmorphic features, microcephaly, intellectual disability, language delay, growth retardation, and corpus callosum dysgenesis were commonly reported. Hence, 6q25 microdeletion is a rare condition. In patients with dysmorphic features, microcephaly, growth retardation, intellectual disability, language delay and corpus callosum dysgenesis, 6q25 microdeletion should be considered in the differential diagnosis and chromosomal microarray analysis should be performed to confirm the diagnosis.

Keywords: 6q25 microdeletion, facial dysmorphism, growth retardation, intellectual disability, language delay

Introduction

6q25 microdeletion, a rare chromosome disorder, has been associated with growth restrictions, abnormal head shape, craniofacial anomalies, hypotonia, seizures, and mild to moderate intellectual disability (1,2). Although a genotype–phenotype correlation has initially been proposed based on the proximal, medial, and distal location of the deletions, the reported cases with molecular karyotyping showed significant clinical heterogeneity, even with overlapping deletions (3,4). Most cases also share delayed verbal communication abilities, although detailed descriptions of speech have not generally been reported (5). 6q25 microdeletion has been extremely rare since the first report in 1975 (6). Herein, we reported a 3-year-old girl with 6q25 microdeletion to highlight this rare condition.

Case Report

The female patient was the first child of healthy non-consanguineous parents. Family history was negative for neurological disorders, behavioral problems, or congenital anomalies. She was born at 39+4 weeks gestation via
vaginal delivery with uneventful pregnancy. Her birth weight and length were 2,600 g and 48 cm without documented occipital frontal circumference and APGAR. After birth, feeding difficulty was noted without history of nasal feeding. Her global development was delayed, with no improvement in her developmental skills with age. She could sit at the age of 15 months, and crawl at the age of two years old. She could not walk without support at the age of 37 months. She could only call “Dad” and “Grandma” at the age of 39 months.

She was first presented to our outpatient clinic at the age of 37 months because of growth retardation, intellectual disability, and language delay. Physical examination showed a height of 85.8 cm [-2 standard deviation (SD)] and a weight of 11.8 kg (-1 ~ -2 SD). Characteristic facial dysmorphism, including long and connected eyebrows, big mouth, wide nasal bridge, high palatine arch, low set ears, and thin hair was noted. The heart, lung, abdomen, limb, and muscle tension were unremarked. Brain magnetic resonance imaging (MRI) revealed dysmorphism of the corpus callosum and stronger T2 signal at basal ganglia.

Standard chromosome banding analysis performed in a local hospital reported “balanced translocation” in chromosome 4 and 8 for this patient and no abnormality for her parents. Chromosomal microarray analysis (CMA) (CMA, CytoScan® HD, Affymetrix) performed in our Medical Genetics Laboratory did not find any microdeletion or microduplication in chromosome 4 or 8, but identified an 8.1-Mb deletion in 6q25.1-q25.3 ([hg19]chr6:152,307,705-160,422,834), which covered 31 genes (ESR1, SYNE1, MYCT1, VIP, FBXO5, MTRF1L, RGS17, OPRM1, CNKSR3, SCAF8, TIAM2, TFB1M, NOX3, ARID1B, SNX9, SYNJ2, SERAC1, GTF2H5, TMEM181, DYNLT1, EZR, RSPH3, TAGAP, FNDC1, SOD2, WTA5, ACAT2, TCP1, MRPL18, MAS1 and IGF2R), as shown in Figure 1.

Figure 1. Chromosomal microarray analysis showed an 8.1-Mb deletion in 6q25.1-q25.3 (152,307,705-160,422,834), which covered 31 genes (100 x 65.9 mm)
Table 1. Clinical features observed in our patient and other reported patients with 6q25 microdeletion

| No/Ref | Sex | Cyto genetic band | Deletion size | Intellectual disability | Language delay | Growth retardation | Dysmorphic features | Microcephaly | Corpus callosum dysgenesis | Limb anomalies | Genital hypoplasia | Hearing loss |
|--------|-----|-------------------|---------------|-------------------------|---------------|-------------------|---------------------|--------------|-----------------------------|---------------|-----------------|-------------|
| Current case | F | 6q25.1-q25.3 | 8.1 Mb | + | + | + | + | - | + | - | - | - |
| Case 1 (13) | F | 6q25.1-q25.3 | 7.8 Mb | + | + | + | + | - | + | - | - | NA |
| Case 2 (14) | M | 6q25.1-q26 | 15.5 Mb | + | + | + | + | + | + | - | + | - |
| Case 3 (1) | M | 6q25.2-q25.3 | 3.77 Mb | + | - | + | + | NA | - | - | + | - |
| Case 4 (1) | F | 6q25.2-q26 | 6.3 Mb | + | + | - | + | + | - | - | NA | - |
| Case 5 (1) | F | 6q24.3-q25.3 | 10.3 Mb | + | + | + | + | + | - | - | NA | - |
| Case 6 (1) | M | 6q25.2-q27 | 13.8 Mb | + | + | + | + | + | - | + | + | - |
| Case 7 (15) | M | 6q25.3 | 1.19 Mb | + | + | - | + | + | + | + | + | - |
| Case 8 (16) | F | 6q25.3 | 1.1 Mb | + | + | + | + | - | + | NA | - | - |
| Case 9 (2) | M | 6q25.3-qter | 10.79 Mb | + | + | NA | + | + | + | NA | - | - |
| Case 10 (5) | F | 6q25.3-qter | 1.1 Mb | + | + | - | + | - | - | - | NA | - |
| Case 11 (5) | M | 6q25.3 | 403 Kb | + | + | - | - | - | NA | - | - | - |
| Case 12 (9) | M | 6q25.1-q25.3 | NA | + | + | + | + | NA | - | - | NA | - |
| Case 13 (14) | M | 6q25.1-q25.3 | NA | + | + | + | + | - | - | - | - | - |
| Case 14 (14) | M | 6q25.1-q26 | NA | NA | NA | + | + | + | - | + | - | - |
| Case 15 (12) | M | 6q25-qter | NA | + | + | - | + | - | - | - | + | - |
| Case 16 (8) | F | 6q25-qter | NA | + | + | - | + | + | - | - | NA | - |
| Case 17 (17) | F | 6q25-qter | NA | + | + | + | + | - | - | - | NA | - |
| Case 18 (10) | M | 6q24.3-qter | NA | NA | NA | + | + | + | - | NA | - | - |
| Case 19 (10) | F | 6q25.3-qter | NA | + | + | + | + | - | - | - | - | NA |
| Case 20 (7) | M | 6q25-qter | NA | + | + | + | + | NA | - | - | - | - |
| Case 21 (11) | F | 6q25-q27 | NA | + | + | + | + | NA | + | NA | - | - |
| Case 22 (11) | M | 6q25-qter | NA | + | + | - | + | - | - | NA | - | NA |
| Total | 13 M | 21/23 | 21/23 | 14/23 | 22/23 | 16/23 | 10/23 | 7/23 | 7/23 | 9/23 |

M: male, F: female; +: present, -: absent, NA: data no available
Discussion

Interstitial deletions of the long arm of chromosome 6 are rare. Since the first report in 1975 (6), the number of patients that have been described in the medical literature remains few (1,2,5,7,8,9,10,11,12,13,14,15,16,17). The phenotype of this syndrome is variable and depends on the breakpoints, location and size of the deletion. Facial dysmorphism, hand malformations, heart defects, microcephaly, intellectual disability, epilepsy, and other neurodevelopmental and neuropsychiatric conditions have been reported. A comparison of the clinical characteristics of our patients with those reported in the literature is shown in Table 1. The clinical features observed in our patient and the other 22 previously reported patients showed that 22 (95.7%) had dysmorphic features, 21 (91.3%) had intellectual disability and language delay, 16 (69.6%) had microcephaly, 14 (60.9%) had growth retardation, and 10 (43.5%) had corpus callosum dysgenesis. The clinical characteristics of our patient overlap with several of these patients. The most common ones include growth retardation, intellectual disability, language delay, and dysmorphic features as well as dysgenesis of the corpus callosum, while microcephaly, hearing loss, limb anomalies and genital hypoplasia are not noted in our patient. These differences may be partly attributed to the varying size and breakpoints of the deletion and more importantly, the gene content of the deleted segment (18). In our patient, CMA showed an 8.1-Mb deletion of 6q25.1-q25.3, which covers 31 genes and only four of these genes (ARID1B, IGF2R, TIAM2 and SYNJ2) have been associated with pathogenicity. Short stature was observed in our patient, while it was not noted in some previous cases (5,8,11,12,15). This may be due to the deletion of the IGF2R gene in our patient. Most other case reports do not specify the deleted genes so further comparison is not possible. However, studies of mice have supported a major role for the IGF receptor pathway in growth: knockout of IGF1, IGF2, or IGF1R results in growth retardation, whereas overexpression of IGF2 results in overgrowth (19,20). The identification of an IGF2 mutation in patients with growth restriction suggests that IGF2 is not only a mediator of intrauterine development but also contributes to postnatal growth (21). The importance of other deleted genes and their contribution to the 6q25 microdeletion are uncertain at this time. Additionally, links between brain anomalies and language delay have been noted in the literature. For instance, de Vasconcelos Hage et al (22) reported that 13 cases of perisylvian polymicrogyria and three cases of corpus callosum hypoplasia were found in 17 patients with language impairment. In typically developing young children, the developmental rate of the splenium of the corpus callosum was associated with vocabulary size (23). In individuals with disfluent speech, the anterior corpus callosum showed significantly lower fractional anisotropy than that of typical controls (24). Hence, in patients with dysmorphic features, microcephaly, intellectual disability, language delay, and corpus callosum dysgenesis, 6q25 microdeletion should be considered in the differential diagnosis and CMA should be performed to confirm the diagnosis.

The mechanism of 6q25 microdeletion is still unclear. The smallest critical region described so far for 6q25 microdeletion have restricted to a 6q25.3 region including two protein-coding genes, ARID1B and ZDHHC14 which was considered to be responsible for the cognitive impairment and brain anomalies observed in their patients (15). The core phenotypic characteristics associated with the 6q25 microdeletion have been observed in a child with a deletion involving only ARID1B which suggested that ARID1B may be one key gene associated with these features (16). Additionally, ARID1B has been associated with multiple syndromes characterized by developmental delay and intellectual disability, such as Coffin-Siris syndrome, and with non-syndromic intellectual disability. It is reported that ARID1B is of great importance for normal human brain development and function. In one study, the phenotype-genotype correlation in seven patients who had various-sized deletions including ARID1B, has shown that haploinsufficiency of ARID1B is related with intellectual disability, speech impairment, and autism as well as corpus callosum abnormalities (25). Therefore, haploinsufficiency of ARID1B appears to be responsible for the clinical findings in our patient.

Conclusion

In summary, 6q25 microdeletion is a rare condition. In patients with dysmorphic features, microcephaly, growth retardation, intellectual disability, language delay, and corpus callosum dysgenesis, 6q25 microdeletion should be considered in the differential diagnosis and CMA should be performed to confirm the diagnosis. MRI of the brain should be considered in all patients with deletions involving 6q25.

Acknowledgment

The authors would like to express their gratitude to the participating family.

Ethics

Informed Consent: Written informed consent was obtained from the parents.
Peer-review: Externally peer-reviewed.

Authorship Contributions

Concept: Mian-Ling Zhong, Chao-Chun Zou, Design: Mian-Ling Zhong, Ye-Mei Song, Chao-Chun Zou, Data Collection or Processing: Mian-Ling Zhong, Ye-Mei Song, Literature Search: Mian-Ling Zhong, Ye-Mei Song, Chao-Chun Zou, Writing: Mian-Ling Zhong.

Financial Disclosure: The authors have indicated that they have no financial relationships relevant to this article to disclose.

References

1. Nagamani SC, Erezi A, Eng C, Ou Z, Chinault C, Workman L, Coldwell J, Sankiewicz P, Patel A, Lupski JR, Cheung SW. Interstitial deletion of 6q25.2-q25.3: a novel microdeletion syndrome associated with microcephaly, developmental delay, dysmorphic features and hearing loss. Eur J Hum Genet 2009;17:573-581. Epub 2008 Nov 26.

2. Abu-Amere KK, Hellani A, Salih MA, Al Hussain A, al Obailan M, Zidan G, Alorainy IA, Bosley TM. Ophthalmologic abnormalities in a de novo terminal 6q deletion. Ophthalmic Genet 2010;31:1-11.

3. Klein OD, Cotter PD, Moore MW, Zanku A, Giliati M, Epstein CJ, Conte F, Rauen KA. Interstitial deletions of chromosome 6q: genotype-phenotype correlation utilizing array CGH. Clin Genet 2007;71:260-266.

4. G Girirajan S, Rosenfeld JA, Coe BP, Parikh S, Goldstein A, Filipink RA, McConnell JS, Angle B, Meschino WS, Nezarati MM, Asamoah A, Jackson KE, Gowans GC, Martin JA, Carmany EP, Stockton DW, Schnur RE, Penney LS, Martin DM, Raskin S, Leppig K, Thiese H, Lebel RR, Siefkas K, Ball S, Shur N, McGuire M, Brasington CK, Spence JE, Martin LS, Clericuzio C, Ballif BC, Shaffer LG, Eichler EE. Phenotypic heterogeneity of genomic disorders and rare copy-number variants. N Engl J Med 2012;367:1321-1331. Epub 2012 Sep 12.

5. Peter B, Lancaster H, Vose C, Fares A, Schrauwen I, Huentelman M. Two novel 6q deletions: a new syndrome. Am J Med Genet A 2017;173:2659-2669. Epub 2017 Aug 2.

6. Milosevic J, Kalicanin P. Long arm deletion of chromosome no. 6 in a mentally retarded boy with multiple physical malformations. J Ment Defic Res 1975;19:139-144.

7. Bartoshesky L, Lewis MB, Pashayan HM. Developmental abnormalities associated with long arm deletion of chromosome No. 6. Clin Genet 1978;13:68-71.

8. Oliveira-Durante MH, Martelli-Soares LR, Sarquis-Cintra T, Machado ML, Lison MP. Distal monosomy of the long arm of chromosome 6 (6q25-6qter) inherited by maternal translocation t (6q;17q). Ann Genet 1990;33:56-59.

9. Narihara K, Tsuji K, Yokoyama Y, Namba H, Murakami M, Matsubara T, Kasai R, Fukushima Y, Seki T, Wakuji K, et al. Specification of small distal 6q deletions in two patients by gene dosage and in situ hybridization study of plasminogen and alpha-L-fucosidase 2. Am J Med Genet 1991;40:348-353.

10. Meng J, Fujita H, Nagahara N, Kashiwai A, Yoshioka Y, Funato M. Two patients with chromosome 6q terminal deletions with breakpoints at q24.3 and q25.3. Am J Med Genet 1992;43:747-750.

11. Valtat C, Galliano D, Mettey R, Toutain A, Moraine C. Monosomy 6q: report on four new cases. Clin Genet 1992;41:159-166.

12. Hopkin RJ, Schorry E, Bofinger M, Milatovich A, Stern HJ, Jayne C, Saal HM. New insights into the phenotypes of 6q deletions. Am J Med Genet 1997;70:377-386.

13. Pirola B, Bortotto L, Giglio S, Piovano E, Janes A, Guerrini R, Zuffardi O. Agenesis of the corpus callosum with Probst bundles owing to haploinsufficiency for a gene in an 8 cM region of 6q25. J Med Genet 1998;35:1031-1033.

14. Sukumar S, Wang S, Hoang K, Vanchiere CM, England K, Fick R, Pagon B, Reddy KS. Subtle overlapping deletions in the terminal region of chromosome 6q: three cases studied using FISH. Am J Med Genet 1999;87:17-22.

15. Michelson M, Ben-Sasson A, Vinkler C, Lebbin-Silver E, Netzer I, Fromkin A, Kivity S, Lerman-Sagie T, Lev D. Delineation of the interstitial 6q25 microdeletion syndrome: refinement of the critical causative region. Am J Hum Genet 2012;158:1395-1399. Epub 2012 May 14.

16. Ronzoni L, Tagliaferri F, Tucci A, Baccarin M, ESPSO S, Milani D. Interstitial 6q microdeletion syndrome: ARID1B is the key gene. Am J Med Genet A 2016;170:1257-1261. Epub 2016 Jan 11.

17. Rivas F, Ruiz C, Rivera H, Möller M, Serrano-Lucas JL, Cantú JM. De novo del(6)(q25) associated with macular degeneration. Ann Genet 1986;29:42-44.

18. Paulraj P, Palumbos JC, Oceanshaw A, Carey J, Toydemir RM. Multiple Congenital Anomalies and Global Developmental Delay in a Patient with Intersitial 6q25-q26 Deletion: A Diagnostic Odyssey. Cytogenet Genome Res 2018;156:191-196. Epub 2018 Nov 16.

19. Baker J, Liu JP, Robertson EJ, Elfstratiadis A. Role of insulin-like growth factors in embryonic and postnatal growth. Cell 1993;75:73-82.

20. Rowden AL. The insulin-like growth factors and feto-placental growth. Placenta 2003;24:803-812.

21. Begemann M, Zirn B, Santen G, Wirthgen E, Soellner L, Büttel HM, Neubauer S. Reduced fractional anisotropy in the anterior corpus callosum is associated with reduced speech fluency in persistent developmental stuttering. Brain Lang 2015;143:20-31. Epub 2015 Oct 21.

22. de Vasconcelos Hage SR, Cendes F, Montenegro MA, Abramides DV, Rossetti-Oliveira-Duarte MH, Martelli-Soares LR, Sarquis-Cintra T, Machado ML, Lison MP. Distal monosomy of the long arm of chromosome 6 (6q25-6qter) inherited by maternal translocation t (6q;17q). Ann Genet 1991;87:17-22.

23. Swanson MR, Wolff JJ, Elison JT, Gu H, Hazlett HC, Botteron K, Styner M, Paterson S, Gerig G, Constantino J, Dager S, Estes A, Vachet C, Piven J; IBIS Network. Spleenium development and early spoken language in human infants. Dev Sci 2017;20:1-13. Epub 2015 Jul 8.

24. de Vasconcelos Hage SR, Cendes F, Montenegro MA, Abramides DV, Guimarães CA, Guerreiro MM. Specific language impairment: linguistic and neurobiological aspects. Arq Neuropsiquiatr 2006;64:173-180.

25. Halgren C, Kjaergaard S, Bak M, Hansen C, El-Schich Z, Anderson CM, Henriksen KF, Hjalgrim H, Kirchhoff M, Böjsha EM, Nielsen M, den Hollander NS, Ruivenkamp CA, Isidor B, Le Caignec C, Zannolli R, Mucciole M, Renieri A, Mari F, Anderlid BM, Andrieux J, Dieux A, Tömmerup N, Bache I. Corpus callosum abnormalities, intellectual disability, speech impairment, and autism in patients with haploinsufficiency of ARID1B. Clin Genet 2012;82:248-255. Epub 2011 Aug 24.